Bone-marrow-derived multipotent progenitor stromal cells — or mesenchymal ... (that is, stem-cell-like property) of these cells is not required for their clinical effect. The final outcome ...

Two small clinical ... stem cell therapies that aim to replace these dead cells in the brain — and stop Parkinson’s and the movement problems, tremors and rigidity that it brings. In both ...

Therapies that use stem cells to repair or replace damaged cells in the brains of patients with Parkinson’s disease have been shown to be safe in early clinical trials. The findings also offer ...

NVDX3 elicited bone formation as early as 12 weeks and functional fusion by 26 weeks in ovine posterolateral fusion (PLF) modelIn phase 1b/2a clinical trial, early bone fusion was observed at 12 ...